Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efavirenz and the CNS: what we already know and questions that need to be answered.

The Journal of antimicrobial chemotherapy - 1 Oct 2015

Apostolova Nadezda, Funes Haryes A, Blas-Garcia Ana, Galindo Maria J, Alvarez Angeles, Esplugues Juan V

Abstract excerpt

The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs in the multidrug regimens used to treat HIV infection, in accordance with its well-demonstrated antiretroviral efficacy and favourable pharmacokinetics. However, growing concern about its adverse effects has sometimes led to efavirenz being replaced by other drugs in the initial treatment selection or to switching of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alkynes
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzoxazines

Share to Central Nervous System

Share to Central Nervous System Diseases

Share to Cyclopropanes

Share to Cytochrome P-450 CYP2B6

Share to Cytochrome P-450 Enzyme Inhibitors

Source

Identifiers

PMID: 26203180
DOI: 10.1093/jac/dkv183

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efavirenz and the CNS: what we already know and questions that need to be answered.PMID 26203180Read ↗

Efavirenz: What is known about the cellular mechanisms responsible for its adverse effectsSemantic proximity Read ↗

In vitro and Ex vivo Neurotoxic Effects of Efavirenz are Greater than Those of Other Common AntiretroviralsSemantic proximity Read ↗

Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral DrugsSemantic proximity Read ↗

Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).Semantic proximity Read ↗

Efavirenz.Semantic proximity Read ↗

Efavirenz in the therapy of HIV infectionSemantic proximity Read ↗

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Semantic proximity Read ↗

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.Semantic proximity Read ↗

CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil.Semantic proximity Read ↗

Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Semantic proximity Read ↗

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.